| Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems S Alon, DR Goodwin, A Sinha, AT Wassie, F Chen, ER Daugharthy, ... Science 371 (6528), eaax2656, 2021 | 274 | 2021 |
| Inhibition of γ-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma R Plentz, JS Park, AD Rhim, D Abravanel, AF Hezel, SV Sharma, ... Gastroenterology 136 (5), 1741-1749. e6, 2009 | 192 | 2009 |
| Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy DL Abravanel, GK Belka, T Pan, DK Pant, MA Collins, CJ Sterner, ... The Journal of clinical investigation 125 (6), 2484-2496, 2015 | 130 | 2015 |
| Actomyosin purse strings: renewable resources that make morphogenesis robust and resilient A Rodriguez‐Diaz, Y Toyama, DL Abravanel, JM Wiemann, AR Wells, ... HFSP journal 2 (4), 220-237, 2008 | 89 | 2008 |
| An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib DL Abravanel, M Nishino, LM Sholl, C Ambrogio, MM Awad Journal of Thoracic Oncology 13 (8), e131-e133, 2018 | 36 | 2018 |
| Inference of single cell profiles from histology stains with the Single-Cell omics from Histology Analysis Framework (SCHAF) C Comiter, ED Vaishnav, M Ciampricotti, B Li, Y Yang, SJ Rodig, M Turner, ... BioRxiv, 2023.03. 21.533680, 2023 | 13 | 2023 |
| Expansion sequencing: spatially precise in situ transcriptomics in intact biological systems. Science 371: eaax2656 S Alon, DR Goodwin, A Sinha, AT Wassie, F Chen, ER Daugharthy, ... | 7 | 2021 |
| I. Consortium, GM Church, AH Marblestone and ES Boyden S Alon, DR Goodwin, A Sinha, AT Wassie, F Chen, ER Daugharthy, ... Science 371, 6528, 2021 | 5 | 2021 |
| The Metastatic Breast Cancer Project: leveraging patient-partnered research to expand the clinical and genomic landscape of metastatic breast cancer and accelerate discoveries E Jain, JGT Zanudo, M McGillicuddy, DL Abravanel, BS Thomas, D Kim, ... medRxiv, 2023.06. 07.23291117, 2023 | 2 | 2023 |
| Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic … J Gómez Tejeda Zañudo, R Barroso-Sousa, E Jain, Q Jin, T Li, ... medRxiv, 2022.07. 11.22277416, 2022 | 2 | 2022 |
| Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet … JGT Zanudo, R Barroso-Sousa, E Jain, J Buendia-Buendia, T Li, N Tayob, ... Cancer Research 82 (4_Supplement), P4-01-06-P4-01-06, 2022 | 2 | 2022 |
| Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial J Gómez Tejeda Zañudo, R Barroso-Sousa, E Jain, Q Jin, T Li, ... Nature Communications 15 (1), 2446, 2024 | 1 | 2024 |
| SlideCNA: Spatial copy number alteration detection from Slide-seq-like spatial transcriptomics data D Zhang, A Segerstolpe, M Slyper, J Waldman, E Murray, O Cohen, ... bioRxiv, 2022.11. 25.517982, 2022 | | 2022 |
| Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic … R Barroso-Sousa, E Jain, Q Jin, T Li, JE Buendia-Buendia, A Pereslete, ... | | 2022 |
| The metastatic breast cancer project-Expanding the clinical, genomic, and transcriptomic landscape of metastatic breast cancer through patient-partnered research E Jain, D Kim, JGT Zanudo, S Balch, M McGillicuddy, BN Tomson, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract PD6-03: Spatio-molecular dissection of the breast cancer metastatic microenvironment DL Abravanel, J Klughammer, T Blosser, Y Goltsev, S Jiang, Y Bai, ... Cancer Research 82 (4_Supplement), PD6-03-PD6-03, 2022 | | 2022 |
| Abstract PD6-02: The metastatic breast cancer project-Expanding the clinical, genomic, and transcriptomic landscape of metastatic breast cancer through patient-partnered research E Jain, D Kim, JGT Zanudo, S Balch, M McGillicuddy, BN Tomson, ... Cancer Research 82 (4_Supplement), PD6-02-PD6-02, 2022 | | 2022 |
| Abstract OT1-19-01: The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research N Wagle, C Painter, E Anastasio, M McGillicuddy, E Jain, TG Hernandez, ... Cancer Research 82 (4_Supplement), OT1-19-01-OT1-19-01, 2022 | | 2022 |
| Molecular spatial mapping of metastatic tumor microenvironment A Regev, J Klughammer, D Abravanel US Patent App. 17/156,392, 2021 | | 2021 |
| Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem … O Cohen, P Mao, U Nayar, JE Buendia-Bue, D Kim, E Jain, K Helvie, ... Cancer Research 80 (4_Supplement), GS2-02-GS2-02, 2020 | | 2020 |
Nikhil WagleDana-Farber Cancer Institute, Harvard Medical School / Broad Institute of MIT and HarvardAdresse e-mail validée de dfci.harvard.edu
